There is still a clinical need for corticosteroid-sparing treatments for immunobullous disease in Australia and the availability of rituximab as a first-line treatment would do much to fill the gap. The monoclonal antibody directed against CD20-expressing B-lymphocytes was FDA listed for this indication in 2018 and by the European Medicine Agency (EMA) in March this ...
Rituximab needed for its steroid sparing effect in immunobullous disease
By Mardi Chapman
27 May 2019